REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
PubMedClinical Trial

Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial.

Gonzales Mitzi M, Garbarino Valentina R, Kautz Tiffany F, Palavicini Juan Pablo, Lopez-Cruzan Marisa, Dehkordi Shiva Kazempour, Mathews Julia J, Zare Habil, Xu Peng, Zhang Bin
Nature medicine2023DOI: 10.1038/s41591-023-02543-w

Citations

0

Subjects

Non-Human

Study Context

This clinical trial followed a structured protocol to evaluate outcomes. The controlled methodology adds credibility to the reported results.

Citation

Gonzales Mitzi M, Garbarino Valentina R, Kautz Tiffany F et al.. (2023). Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial.. Nature medicine. https://doi.org/10.1038/s41591-023-02543-w

View full text on PubMed

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.